Johnson and Johnson reported full-year revenue of more than $82 billion for the first three quarters

On October 30, the third quarter profit doubled, and Johnson and Johnson reported the latest financial results, with total revenue of $60,109 million in the first three quarters of 2020, down 2% yoY, and net income of $12.976 billion, up 16.8% year-on-year.
forecast full-year sales of $82 billion to $82.8 billion, flat to 1 percent year-on-year.
the third quarter of 2020, Johnson and Johnson achieved revenue of US$21,082 million, up 1.7% YoY, and net income of US$3.554 billion, up 102.7% YoY, according to earnings.
third quarter sales by region, U.S. sales were $11,086 million, up 2.7% YoY; Sales were $3.881 billion, down 2.7 percent year-on-year, while consumer health sales were $3.514 billion, up 1.3 percent year-on-year, pharmaceutical sales were $11.418 billion, up 5 percent year-on-year, and medical device sales were $6.15 billion, down 3.6 percent year-on-year.
Among them, for the medical device section business, the surgical business achieved sales of US$2.152 billion, a decrease of 6.9% YoY, orthopaedic business achieved sales of RMB2,083 million, a decrease of 2.6% YoY, vision business achieved sales of RMB1,081 million, a decrease of 9.4% YoY, and access solutions business achieved sales of US$836 million, an increase of 12.9% YoY.
third-quarter results were negatively impacted by the new crown outbreak, but the company did make progress throughout the quarter as countries and states began to gradually reopen.
such as sales in the U.S., but the final impact of the new crown outbreak on annual sales of medical devices remains highly volatile and will continue to grow as the region reopens and a wave of viruses continues.
For the first three quarters of the results, Johnson and Johnson's medical device business achieved sales of RMB16.37 billion, down 15.3% YoY, of which: Surgical Business achieved sales of US$5.803 billion, down 17.8% YoY; $5,572 million, down 15.1% YoY; Vision business achieved sales of $2.843 billion, down 18.4% YoY; and Intervention Solutions achieved sales of $2.153 billion, down 3.1% YoY.
's device business fell 21% in the first half of the year compared with first-half results, and the Johnson and Johnson device sector has rebounded significantly in the third quarter, with John Wolk, chief financial officer, predicting that surgery could recover from the third quarter and that the situation would improve further in the fourth quarter.
, chief executive of Johnson and Johnson, also said that medical devices were indeed experiencing a short-term negative impact, but that medical devices had traditionally been a strong market and that the fundamentals of the market remained the same.
" in July, Johnson and Johnson released its 2020 half-year financial report, showing that its global revenue for the first half of the year was $39,027 million, down 3.8 percent from a year earlier, including $10.22 billion for its medical device business, down 21.1 percent from a year earlier.
According to its semi-annual report, all four major businesses in the johnson and johnson medical device sector declined, including: revenue from the interventional solutions business was $1,317 million, down 11.2% YoY; orthopaedics revenue was $3.489 billion, down 21.2% YoY;
for orthopaedic segment: Hip business revenue of $563 million, down 22.3% YoY, international market down 25.4%, U.S. market down 20.1%, knee business revenue of $517 million, down 30.1% YoY, international market It fell 34.6 percent, the U.S. market fell 27.1 percent, the trauma business reported revenue of $1,207 million, down 11.1 percent from a year earlier, and the U.S. market fell 7.6 percent, while revenue from spine and other businesses fell 25.1 percent to $1,202 million.
Before that, in April this year, when Johnson and Johnson issued a quarterly report, it said that the impact of the outbreak, the world is canceling or postponing the selection of surgery to save resources to treat patients with new coronary pneumonia, which led to a very big blow to Johnson and Johnson's medical device business.
starting at the end of 2019, selected surgery in China is slowing, and by mid-March hospitals in Japan, South Korea, Europe and the United States are postponing or canceling it.
addition, Johnson and Johnson executives say that working from home during the outbreak, with fewer people out and fewer injuries, means that traumatic surgery is also significantly reduced.